INTRODUCTION
============

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease in life births and can be repaired safely at a young age \[[@ezaa049-B1]\]. However, long-term survival and freedom from reintervention are limited by the presence of ventricular arrhythmia, sudden death and heart failure \[[@ezaa049-B2], [@ezaa049-B3]\]. Ventricular tachyarrhythmia in repaired TOF patients is presumed to be the primary cause of sudden death. In the current paradigm, it is believed that chronic volume overload, caused by residual pulmonary regurgitation (PR), leads to right ventricular (RV) dilatation. This ultimately predisposes for electromechanical dissociation and heart failure \[[@ezaa049-B3]\]. Pulmonary valve replacement (PVR) treats PR and results in RV remodelling during the first postoperative years \[[@ezaa049-B6]\]. However, RV reverse remodelling does not occur in every patient and adverse events still occur frequently after PVR \[[@ezaa049-B7]\]. It is currently unknown how to define and determine the optimal time frame within which PVR should be performed.

QRS duration assessed through standardized 12-lead electrocardiogram may potentially be a prognostic electrocardiographic biomarker for adverse cardiac events. A QRS duration exceeding 170--180 ms has repeatedly been indicated as independent predictor for malignant ventricular arrhythmia and sudden cardiac death \[[@ezaa049-B3], [@ezaa049-B8]\]. Furthermore, prolonged QRS duration is associated with regional wall motion abnormalities, RV dilatation \[[@ezaa049-B5]\], increased biventricular wall mass \[[@ezaa049-B9]\] and decreased left ventricular ejection fraction \[[@ezaa049-B9]\]. QRS duration can, therefore, be a potentially meaningful surrogate marker reflecting the impact of chronic severe PR and RV dilatation. A better understanding of the temporal evolution of QRS duration in patients with corrected TOF before and after PVR could improve timing of PVR.

We determined the temporal evolution of QRS duration before and after PVR in a consecutive cohort of corrected TOF patients.

METHODS
=======

All consecutive patients (*N* = 158) who underwent surgical PVR in the Erasmus University Medical Center Rotterdam between August 1987 and November 2017 after complete correction of ToF with a transannular patch were included retrospectively. Gore-Tex transannular patches were used without monocusp reconstruction. Patients with pulmonary atresia, ventricular septal defects and systemic collateral arteries were excluded. The institutional review board approved this study and waived individual informed consent (MEC 12-477).

Indication and surgical technique
---------------------------------

All patients were discussed in structured multidisciplinary meetings (congenital heart team meeting) including congenital cardiologists, congenital cardiac surgeons and radiologist, prior to interventions. All indications for PVR were severe PR with signs of progressive RV dilatation or reduced function with or without cardiac-related symptoms. PVR was generally performed through median sternotomy, using standard cardiopulmonary bypass as previously described. In our centre, cryopreserved homografts have been and still are exclusively used for RV outflow tract reconstruction, given their excellent results in terms of structural valve deterioration, and low rates of endocarditis and valve thrombosis \[[@ezaa049-B10]\].

Study design
------------

After discharge, patients were followed though our outpatient clinic at 1 week, 6 weeks, 6 months and annually thereafter. Standardized 12 lead (25 mm/s, 10 mm/mV) surface electrocardiograms (ECGs) were acquired during every visit to our outpatient clinic regardless of symptomatology. Valve-related events and mortality were reported according to the guidelines for reporting valve-related mortality and morbidity \[[@ezaa049-B11]\]. Follow-up within 2 years of study closing (February 2018) was available for 151 (97.4%) patients discharged alive after PVR. Four patients were lost to follow-up after PVR due to emigration (*n* = 3) and unknown reasons (*n* = 1). QRS duration as marker of ventricular depolarization was extracted from computerized calculations based on the VERITAS™ ECG algorithm (Mortara Instrument, 2018, Milwaukee, WI, USA). Paced rhythms were excluded from the analysis and ECGs were censored in case of re-PVR. Sixteen (10.1%) patients underwent pacemaker implantation 22.0 ± 10.8 years after correction of which 4 before PVR, 10 after PVR and 2 concomitantly to PVR. An integrated assessment of the severity and physiology of PR was based on a multi-window perspective using transthoracic colour flow and pulsed-wave Doppler echocardiography and qualitatively graded from none, light, moderate and severe. Significant regurgitation was defined as moderate or severe regurgitation \[[@ezaa049-B12]\].

Statistical analysis
--------------------

Continuous outcomes are reported as means ± standard deviations or medians with range, as appropriate. Continuous variables between groups were compared using independent samples *t*-tests, one-way analysis of variance (ANOVA) analysis, or Kruskal--Wallis tests, as appropriate. Frequencies were presented with percentages and compared using *χ*^2^ tests. Correlations between continuous baseline variables were calculated using Pearson correlation, and reported with 2-tailed significance levels. Time-dependent outcomes were analysed using life tables and visualized with Kaplan--Meier plots as a function of time to or since PVR. Sex, age at correction, time interval between correction and PVR, age at PVR, length at PVR, weight at PVR, creatinine (mmol/l) at PVR and QRS duration at PVR were studied as potential risk factors by univariate and multivariate Cox proportional hazards models, using a backward stepwise elimination process with a threshold of (*P* \> 0.05) (Table [1](#ezaa049-T1){ref-type="table"}). Missing values were considered missing at random and not imputed due to the very small amount of missing values. Analyses were exploratory in nature and no adjustment for multiple testing was performed.

Continuous repeated measurements of QRS duration were analysed using linear mixed-effects modelling \[[@ezaa049-B13]\]. A random effects structure with time was used to account for correlations between repeated measurements in the same patient and irregularly timed measurements. QRS duration was modelled as a function of time to PVR, including fixed effects for sex and age at correction. Time in relation to PVR was entered as a natural cubic spline with 2 internal knots. Furthermore, potential interaction effects between age at correction, sex and time between correction and PVR, were explored. Effect plots were provided to illustrate the temporal evolution of QRS duration of an average patient. Given a significant trend towards earlier repair in our practice as well as contemporary surgical practice, early and late repair were defined as correction at the age of 6 months and 5 years, respectively.

Statistical analyses were performed with SPSS (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.) and R (LME4 package) \[R Core Team (2016)\].

RESULTS
=======

Baseline patients and surgical characteristics
----------------------------------------------

A total of 158 consecutive patients underwent surgical PVR after previous ToF correction with a transannular patch. Median age at correction was 2.0 years (range 5 days--29.5 years) and 90 (57%) were males (Table [2](#ezaa049-T2){ref-type="table"}). Mean time between correction and PVR was 23.4 ± 8.2 years (range 1.93--44.) at a mean age of 28.0 ± 10.7 years (range 2.1--66.4). Moderate or severe regurgitation were present in 155 (98.1%) patients before PVR. [Supplementary Material, Fig. S1A--C](#sup1){ref-type="supplementary-material"} shows the trend during the study period of age at ToF correction, at PVR and the time between correction and PVR. The figures indicate an increasingly younger age at correction and a relatively stable time interval between correction and subsequent PVR.

###### 

Baseline, surgical and diagnostic characteristics

                                                                                   Overall       Interval \<10 years   Interval 10--20 years   Interval 20--30 years   Interval \>30 years   *P*-value[^a^](#tblfn1){ref-type="table-fn"}
  -------------------------------------------------------------------------------- ------------- --------------------- ----------------------- ----------------------- --------------------- ----------------------------------------------
  Patients, *n* (%)                                                                158 (100)     11 (7.0)              42 (26.6)               73 (46.2)               32 (20.3)             
  Male gender, *n* (%)                                                             90 (57.0)     7 (63.6)              19 (45.2)               41 (56.2)               23 (71.9)             0.140
  Shunt before correction, *n* (%)                                                 43 (27.2)     3 (27.3)              15 (35.7)               15 (20.5)               10 (31.3)             0.330
  Age at correction (years), mean ± SD                                             4.6 ± 5.5     3.1 ± 5.5             4.9 ± 7.0               3.7 ± 3.8               6.9 ± 6.0             0.035
  Time correction-PVR (years), mean ± SD                                           23.4 ± 8.2    6.7 ± 2.3             16.3 ± 2.9              25.0 ± 2.8              34.5 ± 3.3            \<0.001
  Age at PVR (years), mean ± SD                                                    28.0 ± 10.7   9.8 ± 5.9             21.1 ± 7.2              28.8 ± 5.7              41.5 ± 7.8            \<0.001
  Haemodynamic indication, *n* (%)                                                                                                                                                           
   Severe regurgitation                                                            137 (86.7)    7 (63.6)              38 (90.5)               64 (87.7)               28 (87.5)             0.264
   Severe stenosis                                                                 3 (1.9)       1 (9.1)               1 (2.4)                 1 (1.4)                 0 (0)                 
   Mixed                                                                           18 (11.4)     3 (27.3               3 (7.1)                 8 (11.)                 4 (12.5)              
  RVOT peak gradient (mmHg) (*n* = 145), mean ± SD                                 18.1 ± 20.7   46.1 ± 53.3           20.0 ± 17.5             14.9 ± 13.7             13.7 ± 11.0           \<0.001
  BSA[^b^](#tblfn2){ref-type="table-fn"} (*n* = 139) mean ± SD                     1.78 ± 0.27   1.15 ± 0.35           1.61 ± 0.21             1.84 ± 0.20             1.94 ± 0.17           \<0.001
  Previous heart operations[^C^](#tblfn3){ref-type="table-fn"} (%), *n* (%)                                                                                                                  
   1                                                                               101 (63.9)    7 (63.6)              24 (57.1)               48 (65.8)               22 (68.8)             0.640
   2                                                                               46 (29.1)     3 (27.3)              13 (31.0)               22 (30.1)               8 (25.0)              
   3                                                                               9 (5.9)       1 (9.1)               3 (7.1)                 3 (4.1)                 2 (6.3)               
   4                                                                               2 (1.3)       0 (0)                 2 (4.8)                 0 (0)                   0 (0)                 
  Pre-PVR QRS duration[^d^](#tblfn4){ref-type="table-fn"} (*n* = 132), mean ± SD   150 ± 31      141 ± 32              147 ± 31                150 ± 30                155 ± 35              0.674
  Elective (\>24 h), *n* (%)                                                       147 (93.0)    10 (90.9)             38 (90.5)               69 (94.5)               30 (93.8)             0.855
  Diuretic use (*n* = 156), *n* (%)                                                15 (9.6)      1 (9.1)               4 (9.8)                 8 (11.1)                2 (6.3)               0.895
  Sinus rhythm (*n* = 156), *n* (%)                                                137 (87.8)    11 (100)              38 (92.7)               63 (87.5)               25 (78.1)             0.154
  Creatinine (mmol/l) (*n* = 153), mean ± SD                                       70 ± 19       43 ± 16               63 ± 17                 74 ± 14                 79 ± 20               \<0.001
  Cross-clamp time (*n* = 141), mean ± SD                                          22 ± 43       47 ± 34               29 ± 42                 17 ± 41                 31 ± 48               0.101
  Perfusion time (*n* = 147), mean ± SD                                            111 ± 63      106 ± 50              125 ± 62                101 ± 66                115 ± 58              0.296
  Pulmonary allograft[^e^](#tblfn5){ref-type="table-fn"} (*n* = 154), *n* (%)      154 (97.5)    11 (100)              40 (95.2)               72 (98.6)               31 (96.9)             0.665
  Diameter of allograft (mm) (*n* = 157), median (range)                           24 (15--28)   22 (15--25)           24 (21--28)             24 (21--28)             24 (21--28)           0.440
  Hospital mortality, *n* (%)                                                      3 (1.9)       0 (0)                 1 (2.4)                 1 (1.4)                 1 (3.1)               0.889
  ECG                                                                                                                                                                                        
   Total number available, *n*                                                     3549          137                   809                     1816                    787                   
    Pre-PVR (%), *n* (%)                                                           323 (9.1)     11 (8.0)              49 (6.1)                185 (10.2)              78 (9.9)              0.242
   Unique patients, *n* (%)                                                        157 (99.4)    11 (100)              41 (97.6)               73 (100)                32 (100)              
   ECGs/patient, *n*                                                               22.5          12.5                  19.7                    24.9                    24.6                  0.142
  Echocardiography                                                                                                                                                                           
   Total number available, *n*                                                     1747          130                   472                     821                     324                   
    Pre-PVR (%), *n* (%)                                                           533 (30.5)    29 (22.3)             85 (18.0)               282 (34.3)              137 (42.3)            0.151
   Unique patients, *n* (%)                                                        156 (98.7)    11 (100)              41 (97.6)               73 (100)                31 (96.9)             
   Echos/patient, *n*                                                              11.1          11.8                  11.5                    11.2                    10.1                  0.242
  Follow-up duration (years), mean ± SD                                            9.6 ± 9.6     12.3 ± 10.8           12.3 ± 8.0              9.3 ± 5.3               7.3 ± 6.2             0.010
  Max post-PVR QRS duration, mean ± SD                                             158 ± 37      142 ± 35              153 ± 34                159 ± 32                168 ± 48              NA

Continuous variables between groups are compared using one-way ANOVA analysis or Kruskal--Wallis tests.

According to the formula of Mosteller.

All previous open heart surgeries, including complete correction.

QRS duration nearest in time but within 1 year prior to PVR.

Pulmonary allograft or aortic allograft.

BSA: body surface area; NA: not applicable; PR: pulmonary regurgitation; PVR: pulmonary valve replacement; RVOT: right ventricular outflow tract; SD: standard deviation.
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Cox proportional hazards model for cardiac death

  Variables               Univariable            Multivariable                          
  ----------------------- ---------------------- --------------- ---------------------- -------
  Cardiac death                                                                         
   Sex                    0.204 (0.042--0.989)   0.048           0.130 (0.016--1.085)   0.058
   Age at correction      1.111 (1.030--1.198)   0.006                                  
   Time correction-PVRb   1.119 (1.034--1.211)   0.005           1.097 (1.002--1.200)   0.005
   Age at PVR             1.095 (1.043--1.150)   \<0.001                                
   Length at PVR          1.058 (0.996--1.123)   0.069                                  
   Weight at PVR          1.053 (1.009--1.098)   0.017                                  
   Creatinine (mmol/l)    1.032 (0.988--1.079)   0.160                                  
   QRS-duration pre PVR   1.004 (0.981--1.027)   0.733                                  

Because of the correlations between the covariates and linear dependency between age at correction, time-between correction and PVR, age at PVR, length and weight at PVR, only 1 (i.e. time between correction and PVR) was entered in the multivariable part of the analysis.

HR: hazard ratio; PVR: pulmonary valve replacement.

Clinical outcome
----------------

Hospital survival was 98.1% (*n* = 155). Three patients (1.9%) died shortly after PVR of sudden cardiac death presumably due to arrhythmia (*n* = 1), severe oesophageal bleeding and pulmonary infection after concomitant tracheal resection (*n* = 1) and repeated rhythm disturbances with severe biventricular heart failure (*n* = 1). All 3 patients had severe PR with RV dilatation and symptoms. Mean follow-up time after PVR was 10.0 ± 7.0 years (median 9.3, range 0.3--28.7 years, total 1555 patient years), during which 18 patients underwent a second PVR (6 surgically, 12 percutaneously), after a mean period of 7.9 ± 5.5 years. Freedom from re-PVR after 10 and 15 years was 84 ± 4% and 81 ± 5%, respectively.

Late cardiac death was observed in 9 patients, of whom 3 (33%) were also classified as having an extremely prolonged QRS duration (\>230 ms) post-PVR (Table [3](#ezaa049-T3){ref-type="table"}). The relative risk of cardiac death in patients with an extremely prolonged QRS duration was 7.25 \[95% confidence interval (CI) 2.48--8.74; *P* = 0.002\]. The 9 patients who died of cardiac causes were corrected at an average age of 12.4 ± 5.4 years (median 12.7, 4.5--23.0) and underwent PVR 28.6 ± 5.6 years later (median 29.2, range 18.4--36.8). They died 11.0 ± 4.2 years after PVR, at an average age of 52.0 ± 8.9 years. Cumulative freedom from cardiac death of all hospital survivors after 10 and 15 years post-PVR was 90 ± 4% and 83 ± 6%, respectively (Fig. [1](#ezaa049-F1){ref-type="fig"}).

![Kaplan--Meier curve depicting cumulative freedom from cardiac death after PVR (solid line) along with 95% confidence intervals (dotted lines). PVR: pulmonary valve replacement.](ezaa049f1){#ezaa049-F1}

![](ezaa049f3){#ezaa049-F3}

###### 

Characteristics of patients with extreme QRS (\>230) and/or late cardiac death

  Gender   Age at correction   Age at PVR   Time correction-PVR   Age at last follow-up/death   Late cardiac death   Extreme QRS   PM                 Max QRS   PM                 Max QRS before PM
  -------- ------------------- ------------ --------------------- ----------------------------- -------------------- ------------- ------------------ --------- ------------------ -------------------
  Male     9.3                 40.7         31.4                  48.8                          Heart failure        Yes           After PVR          336       After PVR          206
  Male     13.4                48.4         35.0                  64.3                          Heart failure        Yes           Never              260       Never              260
  Male     13.0                42.2         29.2                  53.2                          SUUD                 Yes           Never              260       Never              260
  Female   11.8                41.0         29.2                  56.7                          SUUD                 No            Never              174       Never              174
  Male     16.5                43.7         27.2                  53.3                          Heart failure        No            Never              142       Never              142
  Female   12.7                38.8         26.1                  51.6                          Heart failure        No            Never              222       Never              222
  Male     7.0                 43.8         36.8                  54.7                          Heart failure        No            Never              194       Never              194
  Male     4.5                 28.9         24.3                  31.2                          SUUD                 No            Never              178       Never              178
  Male     23.0                41.4         18.4                  54.3                          Heart failure        No            Never              186       Never              186
  Male     4.4                 44.4         40.0                  47.8                          Alive                Yes           Never              250       Never              250
  Male     8.4                 41.7         33.2                  60.8                          Alive                Yes           Never              252       Never              252
  Female   2.0                 24.5         22.4                  43.4                          Alive                Yes           At PVR             299       At PVR             NA
  Male     8.8                 37.8         29.0                  50.6                          Alive                Yes           After correction   292       After correction   NA
  Female   0.2                 23.4         23.2                  39.1                          Alive                Yes           After PVR          226       After PVR          226
  Male     10.5                43.8         33.2                  56.4                          Alive                Yes           After PVR          239       After PVR          234
  Male     2.3                 32.4         30.2                  41.5                          Alive                Yes           After PVR          233       After PVR          176

NA: not applicable; PM: pacemaker; PVR: pulmonary valve replacement; SUUD: sudden unexplained unexpected death.

QRS duration over time
----------------------

In all but 1 patient, ECGs were available (Table [2](#ezaa049-T2){ref-type="table"}). One patient underwent correction in 1976 and subsequent PVR in 1991 after which he died 14 days later due to severe rhythm disturbances. No ECGs could be retrieved from this patient.

Patients are presented in different groups based on the time interval between ToF correction and PVR (interval between ToF correction and PVR \<10 vs 10--20 vs 20--30 vs \>30 years) (Table [2](#ezaa049-T2){ref-type="table"}). The QRS duration prior to PVR was not associated with the time interval between correction and PVR (*r* = 0.089, *P* = 0.311), and was comparable among the 4 groups (*P* = 0.674). However, the time interval between correction and PVR showed significant correlations with other baseline factors. A longer time interval between correction and PVR was correlated with older age at correction (*r* = 0.189, *P* = 0.017), older age at PVR (*r* = 0.864, *P* \< 0.001), higher creatinine (*r* = 0.487, *P* \< 0.001), greater diameter of allograft (*r* = 0.207, *P* = 0.009), greater height at PVR (*r* = 0.443, *P* \< 0.001) and higher weight at PVR (*r* = 0.603, *P* \< 0.001).

Figure [2](#ezaa049-F2){ref-type="fig"}A and B provides a panel of effect plots of QRS duration over time before and after PVR. Temporal trends are depicted for male and female patients corrected early (Fig. [1](#ezaa049-F1){ref-type="fig"}A) and late (Fig. [1](#ezaa049-F1){ref-type="fig"}B). Different time intervals between correction and PVR are vertically depicted (10, 20, 30 and 40 years after correction, respectively). Our online application (<https://cts-erasmusmc.shinyapps.io/fallotqrs/>) provides results for any combination of choice. The figure illustrates that no major changes occur in QRS duration before PVR, and QRS duration is comparable right before PVR, regardless of duration since correction. However, important changes in the overall slope of the evolution of QRS duration can be observed in patients who undergo PVR beyond a certain period. After PVR, a longer time period between correction and PVR (*P* \< 0.001), and an older age at correction (*P* = 0.0185) were both significantly and independently associated with progression of QRS duration.

![Panel figure of the longitudinal QRS (in ms) evolution for 2 fictional patients of both genders. Age at correction of 6 months (**A**) and 5 years (**B**) were chosen. Time between correction and PVR increases from 10 to 40 years (vertically). Thus, the figure indicates the longitudinal evolution of QRS duration for a child corrected at 6 months (**A**) and 5 years (**B**), for both males and females, given 4 different moments of PVR after correction (vertically depicted; 10, 20, 30 and 40 years, respectively). Post-PVR evolution of QRS duration shows a progressive prolongation in patients who underwent PVR 30 and 40 years after correction, despite comparable QRS durations right before PVR. PVR: pulmonary valve replacement.](ezaa049f2){#ezaa049-F2}

Pacemaker and ICD
-----------------

Among hospital survivors without a pacemaker, the time interval between correction and PVR was not associated with the hazard of late pacemaker implantation \[hazard ratio (HR) 1.035, 95% CI 0.958--1.118; *P* = 0.383\]. A longer time interval between correction and PVR was, however, associated with an increased hazard of late implantation of an implantable cardioverter-defibrillator (ICD) (HR 1.137, 95% CI 1.039--1.244; *P* = 0.005).

DISCUSSION
==========

This study is the first to show an association between timing of PVR and QRS duration using innovative and advanced statistics to model the individual long-term evolution of QRS duration before and after PVR in a homogenous group of corrected ToF patients. QRS duration after PVR is significantly associated with a longer time interval between initial correction and PVR, a higher age at correction and sex. In patients who undergo early ToF correction, progressive QRS prolongation after PVR can be prevented by intervening within ∼17 years after correction. In patients with ToF correction at a later age, progressive QRS prolongation after PVR can be prevented by intervening within ∼15 years after correction. The time interval between ToF correction and PVR is therefore associated with postoperative QRS duration, cardiac death and the hazard of postoperative ICD implantation. QRS duration is an important risk factor before and after PVR in corrected ToF patients, and prevention of prolongation might improve the outcome of these patients.

PVR and QRS duration
--------------------

Few published studies have investigated the relation between PVR and QRS duration \[[@ezaa049-B14]\]. However, the results are heterogeneous with some authors reporting a stable QRS duration \[[@ezaa049-B17], [@ezaa049-B19], [@ezaa049-B20], [@ezaa049-B22], [@ezaa049-B28]\], some an increase \[[@ezaa049-B16]\] and some a decrease \[[@ezaa049-B6], [@ezaa049-B15], [@ezaa049-B18], [@ezaa049-B21], [@ezaa049-B25], [@ezaa049-B27]\] after PVR in corrected ToF patients. Therrien *et al*. \[[@ezaa049-B28]\] were the first to report a stabilization in QRS duration after PVR in corrected ToF patients compared to a control group who had not undergone PVR. van Huysduynen *et al*. \[[@ezaa049-B29]\] were the first to report a decline in QRS duration following PVR in 26 patients with corrected ToF with at least moderate regurgitation. Oosterhof *et al*. studied 99 corrected TOF patients who underwent a first PVR and reported an initial decline in mean QRS duration directly post-surgery. QRS duration increased, however, during a median follow-up of 5 years in patients with preoperative QRS \>120 ms. In patients with a preoperative QRS \<120 ms, no increase was reported \[[@ezaa049-B30]\]. The mixed results of QRS duration could potentially also be explained by undisclosed differences in time interval between correction and PVR. Mixed-effect modelling enabled us to model the variability that is inherent to and only observable in a longitudinal design that considers irregularly scheduled and collected measurements and accepts a non-linear evolution.

QRS prolongation as risk factor
-------------------------------

Prolongation of QRS duration has been reported despite successful PVR and is predictive of adverse outcome \[[@ezaa049-B16], [@ezaa049-B25], [@ezaa049-B29]\]. As multiple studies have demonstrated the malignant nature of QRS progression as a substrate for cardiac dysfunction and increasing depolarization disturbances, preventing this postoperative prolongation seems imperative \[[@ezaa049-B25], [@ezaa049-B29]\]. Scherptong *et al*. \[[@ezaa049-B25]\] reported that a post PVR QRS duration exceeding 180 ms was associated with a reduced freedom from a composite end point including death, re-PVR, ventricular tachyarrhythmia and symptomatic heart failure after 5 years. Stabilization of QRS duration after PVR has occasionally been associated with a reduced frequency of ventricular tachycardia \[[@ezaa049-B18]\]. Harrild *et al*. studied 98 corrected ToF patients who underwent PVR 20 years after correction at a mean age of 5 years. In a later study, QRS duration did not change after PVR, and matched controls with significant PR and RV dilatation who did not undergo PVR showed no differences in reported ventricular tachycardia or death \[[@ezaa049-B17]\]. The average delay to PVR of 19.7 years is close to the time frame proposed by this study with regard to prolongation prevention. Similarly, the change rate of QRS prolongation and older age at correction have been associated with an increased incidence of ventricular tachyarrhythmia and sudden death \[[@ezaa049-B5]\]. These findings underline the clinical importance of QRS duration after PVR and the relevance of preventing progression.

It could be hypothesized that QRS duration is a reflection of RV remodelling, often shown by progressive RV end-diastolic volume \[[@ezaa049-B4], [@ezaa049-B5]\]. The relevance of preventing progressive QRS duration could be similar in that regard as well, aimed at preserving or even improving ventricular function, given that the correlation between QRS duration and RV end-diastolic volume persists after PVR. QRS duration could, therefore, act both as a biomarker for volumetric and functional change, as well as a risk factor for late adverse events. Unfortunately, no serial volumetric data, preferably by magnetic resonance imaging, were available of sufficient patients to conduct a similar analysis. The design of the current study can, however, be adapted with RV volume over time to potentially identify the pivot point to prevent further RV dilatation, heart failure and malignant arrhythmia.

CONCLUSION
==========

The decision whether to intervene in corrected ToF patients should ideally depend on the combination of multiple biomarkers with the clinical state of the patient. QRS duration is an easily obtainable electrocardiographic biomarker with extensive prognostic capabilities in ToF patients suffering from chronic PR who undergo PVR.
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